tion of participants that show noncompliance with study drug (up to 14 days after start of treatment)  NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19)  Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate  Korea/COVID‐19  150, all, 16 years to 99 years  Treatment  Experimental: lopinavir/ritonavir 200 mg/100 m